-
公开(公告)号:US4677125A
公开(公告)日:1987-06-30
申请号:US902109
申请日:1986-08-29
申请人: Masayuki Teranishi , Mitsuru Takahashi , Hisayo Nomoto , Hiroshi Kase , Katsuichi Shuto , Kazuhiro Kubo , Akira Karasawa
发明人: Masayuki Teranishi , Mitsuru Takahashi , Hisayo Nomoto , Hiroshi Kase , Katsuichi Shuto , Kazuhiro Kubo , Akira Karasawa
CPC分类号: C07F9/3808 , C07C59/68 , C07F9/4006 , C07F9/4065 , C07K5/06191 , A61K38/00
摘要: Phosphorus-containing oligopeptide derivatives are prepared by synthetic methods. The compounds exhibit angiotensin converting enzyme-inhibiting action and are, therefore, useful as anti-hypertensive agents.
摘要翻译: 通过合成方法制备含磷寡肽衍生物。 化合物表现出血管紧张素转化酶抑制作用,因此可用作抗高血压药。
-
公开(公告)号:US4668683A
公开(公告)日:1987-05-26
申请号:US841656
申请日:1986-03-20
申请人: Haruki Takai , Yuji Nomoto , Tadashi Hirata , Tetsuji Ohno , Kazuhiro Kubo
发明人: Haruki Takai , Yuji Nomoto , Tadashi Hirata , Tetsuji Ohno , Kazuhiro Kubo
IPC分类号: A61K31/505 , A61P9/04 , C07D401/14 , C07D487/04 , C07D403/14
CPC分类号: C07D401/14 , C07D487/04
摘要: Quinazoline derivatives and their pharmaceutically acceptable acid addition salts having the general formula ##STR1## wherein R.sup.1 and R.sup.2 each represents hydrogen or alkyl;R.sup.3 represents alkyl or substituted alkyl;R.sup.7 and R.sup.8 each represent alkoxy;Z is oxygen or sulfur;m is zero or 1;n is zero or an integer from 1 to 5,exhibit a cardiotonic activity with little tendency to cause tachycardia.
摘要翻译: 喹唑啉衍生物及其药学上可接受的具有通式(I)的酸加成盐,其中R 1和R 2各自代表氢或烷基; R3表示烷基或取代的烷基; R7和R8各自表示烷氧基; Z是氧或硫; m为零或1; n为零或1至5的整数,表现出强心剂活性,几乎不引起心动过速。
-
公开(公告)号:US08445712B2
公开(公告)日:2013-05-21
申请号:US13509513
申请日:2010-11-12
申请人: Masaya Arai , Kazuhiro Kubo , Shoichi Yokoyama , Kenji Kono
发明人: Masaya Arai , Kazuhiro Kubo , Shoichi Yokoyama , Kenji Kono
IPC分类号: C07F9/24
摘要: A phospholipid derivative represented by the following formula (1) wherein each symbol is as described in the specification; a liposome containing the phospholipid derivative, and the like.
摘要翻译: 由下式(1)表示的磷脂衍生物,其中每个符号如说明书中所述; 含有磷脂衍生物的脂质体等。
-
公开(公告)号:US20110193224A1
公开(公告)日:2011-08-11
申请号:US13020126
申请日:2011-02-03
申请人: Hiroyasu Ito , Kazuhiro Kubo
发明人: Hiroyasu Ito , Kazuhiro Kubo
IPC分类号: H01L23/488
CPC分类号: H01L23/3157 , H01L23/3171 , H01L23/562 , H01L24/13 , H01L2224/05022 , H01L2224/05572 , H01L2924/0002 , H01L2924/01322 , H01L2224/05552
摘要: In a semiconductor device, a pad electrode is disposed on a surface of a semiconductor substrate, and a surface-protective film is disposed on the surface of the semiconductor substrate and the pad electrode. The surface-protective film has an opening to expose a part of the pad electrode. A bump electrode is disposed on the part of the pad electrode exposed from the opening, and a bump is disposed on the bump electrode. The surface-protective film further has a slit at a location above the pad electrode. The slit has a frame shape surrounding a periphery of the bump electrode. The slit extends from a surface of the surface-protective film, which is opposite to the semiconductor substrate, and reaches the pad electrode.
摘要翻译: 在半导体器件中,在半导体衬底的表面上设置焊盘电极,并且在半导体衬底和焊盘电极的表面上设置表面保护膜。 表面保护膜具有露出焊盘电极的一部分的开口。 凸起电极设置在从开口露出的焊盘电极的部分上,并且凸起电极上设置有凸块。 表面保护膜还在焊盘电极上方的位置处具有狭缝。 狭缝具有围绕凸起电极的周边的框架形状。 狭缝从表面保护膜的与半导体衬底相对的表面延伸并到达焊盘电极。
-
公开(公告)号:US07495116B2
公开(公告)日:2009-02-24
申请号:US10508704
申请日:2003-03-28
申请人: Chika Itoh , Kazuhiro Kubo , Syunsuke Ohhashi , Tohru Yasukohchi , Hiroshi Kikuchi , Norio Suzuki , Miho Takahashi , Hitoshi Yamauchi
发明人: Chika Itoh , Kazuhiro Kubo , Syunsuke Ohhashi , Tohru Yasukohchi , Hiroshi Kikuchi , Norio Suzuki , Miho Takahashi , Hitoshi Yamauchi
IPC分类号: C07C9/02
CPC分类号: A61K47/24 , A61K8/14 , A61K8/553 , A61K8/556 , A61K8/86 , A61K9/1271 , A61Q19/00 , C07F9/10 , C08G65/2609 , C08G65/3353
摘要: A phospholipid derivative represented by the formula (1) (Z represents a residue of a compound having 3 to 10 hydroxyl groups; AO represents an oxyalkylene group having 2 to 4 carbon atoms; R1CO and R2CO represent an acyl group having 8 to 22 carbon atoms; X represents hydrogen atom, an alkali metal atom, ammonium or an organic ammonium; “a” represents an integer of 0 to 4; “b” represents 0 or 1; Q represents hydrogen atom or methyl group; m represents an average number of moles of the oxyalkylene group added; and m, k1, k2, and k3 are numbers satisfying the following conditions: 3≦m≦200, 9≦m×(k1+k2+k3)≦1000, 1≦k1≦2, 0≦k2≦9 and 0≦k3≦9, and 3≦k1+k2+k3≦10), which is highly safe for living bodies, and is suitably used for solubilization and dispersion of physiologically active substances and the like, or in the fields of drug delivery systems such as liposomes and cosmetics.
摘要翻译: 由式(1)表示的磷脂衍生物(Z表示具有3〜10个羟基的化合物的残基; AO表示碳原子数2〜4的氧化烯基); R1CO和R2CO表示碳原子数为8〜22的酰基 ; X表示氢原子,碱金属原子,铵或有机铵;“a”表示0〜4的整数,“b”表示0或1; Q表示氢原子或甲基; m表示 氧化亚烷基的摩尔数; m,k1,k2和k3是满足以下条件的数:3 <= m <= 200,9 [= mx(k1 + k2 + k3)<= 1000,1 1 = <= 2,0 <= k2 <= 9,0 <= k3 <= 9,3 <= k1 + k2 + k3 = 10),对生物体来说安全性高,适用于溶解分散 的生理活性物质等,或药物递送系统如脂质体和化妆品领域。
-
公开(公告)号:US20060210618A1
公开(公告)日:2006-09-21
申请号:US10541309
申请日:2003-12-12
申请人: Kazuhiro Kubo , Chika Itoh , Syunsuke Ohhashi , Tohru Yasukohchi , Yusuke Ohkawa , Hiroshi Kikuchi , Norio Suzuki , Miho Takahashi , Hitoshi Yamauchi
发明人: Kazuhiro Kubo , Chika Itoh , Syunsuke Ohhashi , Tohru Yasukohchi , Yusuke Ohkawa , Hiroshi Kikuchi , Norio Suzuki , Miho Takahashi , Hitoshi Yamauchi
CPC分类号: A61K9/127 , A61K8/14 , A61K8/553 , A61K9/0014 , A61K9/1273 , A61K47/24 , A61Q19/00 , C07F9/10 , C08G65/2609 , C08G65/3353 , C08G2650/34
摘要: A phospholipid derivative represented by the following formula (1): wherein [PG]k represents a residue of polyglycerin having a polymerization degree of k, wherein k is 2 to 50, R1CO and R2CO independently represent an acyl group having 8 to 22 carbon atoms, symbol “a” independently represents an integer of 0 to 5, symbol “b” independently represents 0 or 1, M represents hydrogen atom, an alkali metal atom, an ammonium, or an organic ammonium, and k1, k2, and k3 represent numbers satisfying the following conditions: 1≦k1≦(k+2)/2, 0≦k2, and k1+k2+k3=k+2. The phospholipid derivative is highly safe for living bodies and can be suitably utilized in drug delivery systems such as liposome, and the like.
摘要翻译: 由下式(1)表示的磷脂衍生物:其中[PG] k表示聚合度为k的聚甘油的残基,其中k为2至50,R 1 CO和R SUP > 2 CO独立地表示具有8至22个碳原子的酰基,符号“a”独立地表示0至5的整数,符号“b”独立地表示0或1,M表示氢原子,碱金属 原子,铵或有机铵,k1,k2和k3表示满足以下条件的数:1 <= k1 <=(k + 2)/ 2,0 <= k2,k1 + k2 + k3 = k + 2。 磷脂衍生物对于活体是高度安全的,并且可以适用于药物递送系统如脂质体等。
-
公开(公告)号:US20050012314A1
公开(公告)日:2005-01-20
申请号:US10769983
申请日:2004-02-03
CPC分类号: B66C23/74 , B62D49/085 , E02F9/18
摘要: To provide a counter weight capable of forming an attaching part to a vehicle frame with high precision, capable of improving attaching precision to this vehicle frame, and further, capable of decreasing a manufacture cost thereof. The counter weight includes a base made of cast iron having an attaching part, whereby the counter weight is attached to a vehicle frame; and a weight part made of a slab material having a block body made of a slab material; wherein the weight part made of the slab material is attached on the above-described base made of cast iron. The outer surface of the above-described weight part made of the slab material is coated with the cover. In addition, the connection plate is attached to the above-described base made of cast iron, the lower end edge of the above-described cover is joined to the base made of cast iron through the above-described connection plate, and the upper end edge of the above-described cover is joined to the upper part of the above-described weight part made of the slab material. Since the base made of cast iron is attached to the vehicle frame, it is possible to form the attaching part to the vehicle frame at a low cost, simply, and with high precession.
摘要翻译: 为了提供能够高精度地形成车架的安装部的配重,能够提高该车架的安装精度,并且还能够降低制造成本。 配重包括由铸铁制成的基座,该基座具有安装部,由此将配重安装在车架上; 以及由具有由坯料制成的块体的板坯材料制成的重量部件; 其特征在于,由所述板坯材料构成的所述重量部分安装在上述由铸铁制成的基座上。 由板坯材料制成的上述重量部分的外表面涂覆有盖。 另外,连接板安装在上述由铸铁制成的基座上,上述盖的下端缘通过上述连接板与铸铁底座接合,上端 上述盖的边缘连接到由板坯材料制成的上述重量部分的上部。 由于将铸铁制成的基座安装在车架上,所以能够以低成本,简单且高进动地将安装部件形成在车架上。
-
公开(公告)号:US5478835A
公开(公告)日:1995-12-26
申请号:US236097
申请日:1994-05-02
申请人: Toshiaki Kumazawa , Masashi Yanase , Hiroyuki Harakawa , Hiroyuki Obase , Shoji Oda , Shiro Shirakura , Koji Yamada , Kazuhiro Kubo
发明人: Toshiaki Kumazawa , Masashi Yanase , Hiroyuki Harakawa , Hiroyuki Obase , Shoji Oda , Shiro Shirakura , Koji Yamada , Kazuhiro Kubo
IPC分类号: A61K31/335 , A61K31/165 , A61K31/18 , A61K31/19 , A61K31/215 , A61K31/235 , A61K31/275 , A61K31/38 , A61K31/435 , A61K31/44 , A61K31/55 , A61P3/06 , A61P9/10 , A61P43/00 , C07C233/65 , C07C235/46 , C07C235/48 , C07C237/40 , C07C323/40 , C07C323/62 , C07C327/26 , C07C331/08 , C07D221/16 , C07D223/20 , C07D233/58 , C07D313/12 , C07D337/12 , C07D471/04 , C07D491/04 , C07D491/044 , C07D495/04 , C07C207/00 , C07C237/00
CPC分类号: C07D491/04 , C07C233/65 , C07D223/20 , C07D313/12 , C07D337/12 , C07C2103/32 , Y10S514/824
摘要: Disclosed is a tricyclic compound represented by the formula (I): ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represents hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, amino, C1-6 alkylamino, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, halogen, nitro, cyano, carboxy, C1-6 alkoxycarbonyl, hydroxymethyl, CR.sup.9 R.sup.10 CO.sub.2 R.sup.11 (wherein each of R.sup.9, R.sup.10 and R.sup.11 independently represents hydrogen or C1-6 alkyl) or CONR.sup.12 R.sup.13 (wherein each of R.sup.12 and R.sup.13 independently represents hydrogen or C1-6-alkyl); R.sup.5 represents hydrogen or C1-6 alkyl; each of R.sup.6, R.sup.7 and R.sup.8 independently represents hydrogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanoyloxy, C1-6 alkylthio, thiocyanato or halogen; X represents CH or N; Y.sup.1 -Y.sup.2 represents CH.sub.2 -O, CH.sub.2 -S(O).sub.n, (wherein n represents 0, 1, or 2), CH.sub.2 CH.sub.2, CH.dbd.CH or CON(R.sup.14) (wherein R.sup.14 represents hydrogen or C1-6 alkyl) and Z represents oxygen or sulfur, or a pharmaceutically acceptable salt thereof. The compound possesses an acyl coenzyme A: cholesterol acyltransferase-inhibiting activity, and thus are expected to have preventive and therapeutic effects on hyperlipemia and arteriosclerosis.
摘要翻译: 公开了由式(I)表示的三环化合物:其中R 1,R 2,R 3和R 4各自独立地表示氢,C 1-6烷基,C 1-6烷氧基,C 1-6烷硫基,氨基, C 1-6烷基氨基,卤代C 1-6烷基,卤代C 1-6烷氧基,卤素,硝基,氰基,羧基,C 1-6烷氧基羰基,羟甲基,CR 9 R 10 CO 2 R 11(其中R 9,R 10和R 11各自独立地表示氢或C 1-6烷基 )或CONR 12 R 13(其中R 12和R 13各自独立地表示氢或C 1-6 - 烷基); R5表示氢或C1-6烷基; R 6,R 7和R 8各自独立地表示氢,C 1-6烷基,羟基,C 1-6烷氧基,C 1-6烷酰氧基,C 1-6烷硫基,氰硫基或卤素; X表示CH或N; Y1-Y2表示CH2-O,CH2-S(O)n,(其中n表示0,1或2),CH2CH2,CH = CH或CON(R14)(其中R14表示氢或C1-6烷基) Z表示氧或硫,或其药学上可接受的盐。 该化合物具有酰基辅酶A:胆固醇酰基转移酶抑制活性,因此预期对高脂血症和动脉硬化具有预防和治疗作用。
-
公开(公告)号:US5120737A
公开(公告)日:1992-06-09
申请号:US764827
申请日:1991-09-24
申请人: Fumio Suzuki , Hiroaki Hayashi , Kazuhiro Kubo , Junichi Ikeda
发明人: Fumio Suzuki , Hiroaki Hayashi , Kazuhiro Kubo , Junichi Ikeda
IPC分类号: C07D493/04
CPC分类号: C07D493/04
摘要: A hexitol derivative represented by formula (I) ##STR1## wherein R represents hydrogen, unsubstituted or lower alkyl-substituted cycloalkyl, lower alkenyl, lower alkoxy, lower alkanoyl, piperidyl or ##STR2## wherein each of m and n independently represents an integer of 0 to 3; each of X, Y and Z independently represents hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkanoyloxy, hydroxyl, halogen or nitro or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:US5053408A
公开(公告)日:1991-10-01
申请号:US508701
申请日:1990-04-13
申请人: Fumio Suzuki , Hiroaki Hayashi , Takeshi Kuroda , Kazuhiro Kubo , Junichi Ikeda
发明人: Fumio Suzuki , Hiroaki Hayashi , Takeshi Kuroda , Kazuhiro Kubo , Junichi Ikeda
IPC分类号: A61K31/00 , A61K31/495 , A61K31/496 , A61K31/505 , A61P9/00 , A61P9/08 , A61P9/10 , C07D493/04 , C07D519/00
CPC分类号: C07D493/04
摘要: Disclosed is a hexitol derivative represented by the formula (I): ##STR1## wherein Q represents a formula selected from the group consisting of ##STR2## wherein a represents NH, O or S;each of b, c and d independently represents CH or N;each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represents hydrogen, lower alkyl, trifluoromethyl, aryl, lower alkanoyloxy, amino, lower alkylamino, lower alkanoylamino, lower alkanoyl, aroyl, halogen, nitro, (CH.sub.2).sub.m OR.sup. 7, (CH.sub.2).sub.m SR.sup.7, (CH.sub.2).sub.m CO.sub.2 R.sup.7 where R.sup.7 represents hydrogen or lower alkyl and m represents an integer of 0 to 3;each of R.sup.5 and R.sup.6 independently represents hydrogen or lower alkyl;U represents >N-- or ##STR3## W represents a single bond, --O-- or --S--; X represents ##STR4## wherein each of Y.sup.1 and Y.sup.2 independently represents hydrogen, lower alkyl, hydroxyl, lower alkanoyloxy, nitrile or phenyl; or Y.sup.1 and Y.sup.2 are combined together to form oxygen;each of Y.sup.3 and Y.sup.4 independently represents hydrogen or lower alkyl; and l is an integer of 0 to 6, and where l is an integer of 2 to 6, each ##STR5## may be the same or different; Z represents hydrogen or nitro; and, n is 2 or 3 or a pharmaceutically acceptable salt thereof. The compounds show prominent coronary vasodilative activities, and are useful in treating angina pectoris and myocardial infarction.
-
-
-
-
-
-
-
-
-